<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TACROLIMUS</span><br/>(tac-rol'i-mus)<br/><span class="topboxtradename">Prograf, </span><span class="topboxtradename">Protopic<br/></span><b>Classifications:</b> <span class="classification">biologic response modifier</span>; <span class="classification">immunosuppressant</span><br/><b>Prototype: </b>Cyclosporine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg, 5 mg capsules; 5 mg/mL injection; 0.1%, 0.03% ointment</p>
<h1><a name="action">Actions</a></h1>
<p>Macrolide antibiotic produced by a soil fungus with immunosuppressant activity more marked than that of cyclosporine. Inhibits
         helper T-lymphocytes by selectively inhibiting secretion of interleukin-2, interleukin-3, and interleukin-gamma; thus reduces
         transplant rejection.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits antibody production (thus subduing immune response) by creating an imbalance in favor of suppressor T-lymphocytes.</p>
<h1><a name="uses">Uses</a></h1>
<p>Liver rejection prophylaxis; rejection prophylaxis for other organ transplants (kidney, heart, bone marrow, pancreas, small
         bowel), moderate to severe atopic dermatitis (e.g., eczema).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acute organ transplant rejection, severe plaque-type psoriasis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tacrolimus or castor oil; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic insufficiency, hyperkalemia, diabetes mellitus, gout, history of seizures, hypertension.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Rejection Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.150.3 mg/kg/d in 2 divided doses q12h, start no sooner than 6 h after transplant; give first oral dose 812 h
               after discontinuing IV therapy <span class="rdroute">IV</span> 0.050.1 mg/kg/d as continuous IV infusion, start no sooner than 6 h after transplant, continue until patient can take
               oral therapy<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> Same as adult but start with upper end of dosage range <span class="rdroute">IV</span> Same as adult but start with upper end of dosage range<br/><br/><span class="indicationtitle">Atopic Dermatitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer to affected area b.i.d., continue for 1 wk after clearing of symptoms<br/><span class="rdage">Child:</span> <span class="rdroute">Topical</span> <i>215 y,</i> Apply thin layer of 0.03% ointment to affected area b.i.d., continue for 1 wk after clearing of symptoms<br/><br/><span class="indicationtitle">Severe Plaque-Type Psoriasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 0.05 mg/kg/d, increase to 0.1 mg/kg/d at week 3 and to 0.15 mg/kg/d at week 6 if necessary<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue cyclosporine at least 24 h before the first dose of tacrolimus.</li>
<li>Convert patient from IV to oral therapy as soon as possible.</li>
<li>Give first oral dose 812 h after discontinuing IV infusion.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Ensure that skin is clean and completely dry before application.</li>
<li>Apply a thin layer to the affected area and rub in gently and completely.</li>
<li>Do not apply occlusive dressing over the site.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute 5 mg/mL ampuls with NS or D5W to a concentration of 0.0040.02 mg/mL, or less for pediatric patients.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give as continuous IV.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span> <b>Phenytoin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store ampuls between 5° and 25° C (41° and 77° F); store capsules at room temperature, 15°30°
            C (59°86° F).
         </li>
<li>Store the diluted infusion in glass or polyethylene containers and discard after 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Headache, tremors, insomnia, paresthesia, hyperesthesia</span> and/or sensations of warmth, circumoral numbness. <span class="typehead">CV:</span> <span class="speceff-common">Mild to moderate hypertension.</span> <span class="typehead">Endocrine:</span> Hirsutism, <span class="speceff-common">hyperglycemia, hyperkalemia, hypokalemia, hypomagnesemia,</span> hyperuricemia, decreased serum cholesterol. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, abdominal pain, gas,</span> appetite changes, <span class="speceff-common">vomiting, anorexia, constipation,</span> diarrhea, ascites. <span class="typehead">Hematologic:</span> <span class="speceff-common">Anemia, leukocytosis, thrombocytopenia purpura</span>. <span class="typehead">Urogenital:</span> UTI, oliguria, nephrotoxicity. <span class="typehead">Respiratory:</span> <span class="speceff-common">Pleural effusion, atelectasis, dyspnea</span>. <span class="typehead">Special Senses:</span> Blurred vision, photophobia. <span class="typehead">Skin:</span> <span class="speceff-common">Flushing, rash, pruritus, skin irritation,</span> alopecia, erythema, folliculitis, hyperesthesia, <span class="speceff-life">exfoliative dermatitis</span>, hirsutism, photosensitivity, skin discoloration, skin ulcer, sweating. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Pain, fever, peripheral edema</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Use with <b>cyclosporine</b> increases risk of nephrotoxicity. <b>Erythromycin,</b> <b>metoclopramide</b> may increase tacrolimus levels; <b>caspofungin,</b> <b>rifampin</b> may decrease levels. <span class="classification">nsaid</span>s may lead to oliguria or anuria. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Erratic and incompletely absorbed from GI tract; absolute bioavailability approximately 1425%; absorption reduced
      by food. <span class="typehead">Peak:</span> PO 14 h. <span class="typehead">Duration:</span> IV 12 h. <span class="typehead">Distribution:</span> Within plasma, tacrolimus is found primarily in lipoprotein-deficient fraction; 7597% protein bound, mainly to albumin
      and alpha<sub>1</sub>-acid glycoprotein; distributed into red blood cells; blood:plasma ratio reported &gt;4; animal studies have demonstrated high
      concentrations of tacrolimus in lung, kidney, heart, and spleen, and similar tissue profile is to be expected in humans; distributed
      into breast milk. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> Metabolites excreted primarily in bile. <span class="typehead">Half-Life:</span> 8.711.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor serum electrolytes, blood glucose, uric acid, BUN, and creatinine clearance periodically.</li>
<li>Monitor kidney function closely; report elevated serum creatinine or decreased urinary output.</li>
<li>Monitor for neurotoxicity, and report tremors, changes in mental status, or other signs of toxicity.</li>
<li>Monitor cardiovascular status and report hypertension.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn complete dosing instructions.</li>
<li>Be aware of potential adverse effects.</li>
<li>Minimize exposure to natural or artificial sunlight while using the ointment.</li>
<li>Notify physician of S&amp;S of neurotoxicity.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>